EGFR and colorectal carcinoma: Among the six patients with an anti-EGFR resistance signature who had comprehensive genomic profiling results available from tissue, four were wild type at the time of initial diagnosis of CRC for the corresponding fusion and/or RAS/RAF alterations that were later detected in ctDNA, consistent with these genomic events being acquired later in tumorigenesis.